tiprankstipranks
Trending News
More News >
Renishaw PLC (GB:RSW)
LSE:RSW
Advertisement

Renishaw (RSW) AI Stock Analysis

Compare
33 Followers

Top Page

GB:RSW

Renishaw

(LSE:RSW)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - 4o)
Rating:69Neutral
Price Target:
4,048.00p
▲(10.30% Upside)
Renishaw's overall stock score reflects a strong financial foundation and positive technical trends, tempered by valuation concerns and mixed earnings call insights. The company's robust balance sheet and cash flow management are significant strengths, while overbought technical indicators and premium valuation present potential risks.
Positive Factors
Product Innovation
Renishaw's focus on product innovation with successful launches enhances its competitive edge, supporting long-term growth across diverse sectors.
Strong Cash Position
A robust cash position provides Renishaw with flexibility for strategic investments, acquisitions, or returning value to shareholders, bolstering financial stability.
Cost Reduction Success
Effective cost management through structural changes enhances profitability and operational efficiency, positioning Renishaw for sustainable growth.
Negative Factors
Declining Profit Margins
Falling profit margins indicate rising costs and potential pricing pressures, which could challenge Renishaw's ability to maintain profitability long-term.
Additive Manufacturing Revenue Decline
A decline in additive manufacturing revenue highlights sector variability and challenges, potentially impacting Renishaw's growth in this innovative area.
Weakness in Automotive Sector
Continued struggles in the automotive sector could hinder Renishaw's revenue growth and market share in key regions, affecting overall performance.

Renishaw (RSW) vs. iShares MSCI United Kingdom ETF (EWC)

Renishaw Business Overview & Revenue Model

Company DescriptionRenishaw plc, an engineering and scientific technology company, designs, manufactures, distributes, sells, and services metrology and healthcare products worldwide. The company offers co-ordinate measuring machine (CMM) products, machine tool probe and software, performance measurement systems, gauging systems, fixtures, and styli for touch probe systems; interferometric laser, magnetic, and optical encoders; additive manufacturing systems; plastics and metal vacuum casting machines; and mapping sensors. It also provides healthcare products, such as dental scanners, neurosurgical robots and accessories, neurosurgical planning software, drug delivery systems, Raman microscopes, craniomaxillofacial customized implants, analysers, and hybrid Raman systems. In addition, the company offers asset financing and travel agency services. It serves the aerospace, agriculture, automotive, construction, consumer electronics, healthcare, power generation, resource exploration, energy, heavy, medical, and precision manufacturing industries, as well as scientific, research, and analysis industries. The company was incorporated in 1973 and is headquartered in Wotton-under-Edge, the United Kingdom.
How the Company Makes MoneyRenishaw generates revenue through multiple streams, primarily from the sale of metrology products, which include probe systems, software, and calibration equipment. The company also earns income from its healthcare division, which focuses on dental and surgical products, including dental CAD/CAM systems and neurostimulation devices. Key revenue streams include direct product sales, after-sales services, and maintenance contracts. Additionally, Renishaw benefits from partnerships with other technology companies and institutions, contributing to its research and development efforts, which help to drive innovation and expand its product offerings. The company also sees growth from international markets, which represent a significant portion of its revenue base, owing to its global presence and distribution networks.

Renishaw Earnings Call Summary

Earnings Call Date:Sep 18, 2025
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Jan 29, 2026
Earnings Call Sentiment Neutral
The earnings call presents a balanced view, with notable strengths in systems business growth, product innovation, and opportunities in China. However, these are countered by challenges in automotive, additive manufacturing revenue decline, and U.S. tariff impacts.
Q4-2025 Updates
Positive Updates
Strong Performance in Systems Business
The systems business in industrial metrology is identified as a high growth area, with positive outlook and rapid business growth potential.
Positive Signs in Additive Manufacturing (AM)
Despite a down year, additive manufacturing ended with a solid order book and positive prospects in defense markets.
Opportunities in China
Good growth and optimism in China with new opportunities in entry-level markets and encoder applications in electronics and semiconductors.
Cost Reduction Success
GBP 24 million cost savings expected from labor and facility closures, with additional productivity initiatives underway.
Product Innovation and Launches
New product launches such as Equator-X, dual-laser RenAM, and ASTRiA encoders are performing well and driving long-term growth.
Strong Cash Position
Nearly GBP 300 million in cash on the balance sheet, with active discussions on capital allocation.
Negative Updates
Weakness in Automotive and Machine Tools
Ongoing weakness in automotive and machine tools, particularly in Germany and Taiwan, affecting the sensors business.
Additive Manufacturing Revenue Decline
Additive manufacturing revenue was down in FY '25, indicating sector variability and challenges.
Consumer Electronics Challenges
Consumer electronics market was down at the group level in 2025, despite being noted as an area of strength.
Impact of U.S. Tariffs
U.S. tariffs have a 1% impact on revenue, leading to price increases to offset additional costs.
Currency Impact
No expected significant currency impact in FY '26, but previous year had a beneficial one-off FX impact.
Company Guidance
During a recent Q&A session following Renishaw's full-year financial results for the fiscal year ending June 30, 2025, multiple metrics and guidance were discussed. CEO Will Lee highlighted mixed performance across various sectors, with industrial metrology facing challenges in Germany and Taiwan, yet showing promise in the shop floor metrology segment. The company aims to enhance market share with innovations like the NC4 Blue product line. In the additive manufacturing sector, despite a decrease in FY '25 revenues, the year concluded with a strong order book, particularly in defense. The session also addressed pricing strategies, noting that U.S. tariff surcharges have transitioned to price increases, impacting revenue by about 1%, or GBP 9 million. Financial metrics included a projected GBP 24 million in cost savings from structural changes, such as facility closures, and a flat currency impact for FY '26. Renishaw is actively discussing capital allocation strategies for its GBP 300 million cash reserve, with no immediate plans disclosed. Additionally, the company anticipates a stable working capital and CapEx of approximately GBP 40 million annually going forward.

Renishaw Financial Statement Overview

Summary
Renishaw demonstrates solid revenue growth and operational efficiency with a robust balance sheet. However, the net profit margin has decreased, impacting overall profitability.
Income Statement
72
Positive
Renishaw's income statement shows stable revenue growth with a 1.41% increase in the latest year. Gross profit margin remains robust at 46.8%, although it has slightly decreased from previous years. The net profit margin has also decreased to 14.0%, indicating some pressure on profitability. However, the company maintains a solid EBIT margin of 15.7% and an EBITDA margin of 22.6%, demonstrating operational efficiency.
Balance Sheet
85
Very Positive
The balance sheet is strong with a very low debt-to-equity ratio of 0.02, indicating minimal leverage and financial risk. The equity ratio is high at 85.9%, reflecting a strong equity base. Return on equity stands at 10.7%, which is decent, though it has declined from previous levels, suggesting reduced profitability on equity.
Cash Flow
68
Positive
Renishaw exhibits a positive free cash flow growth of 686.9% year-over-year, signaling significant improvement in cash generation. The operating cash flow to net income ratio is 1.28, which shows strong cash flow relative to net income. The free cash flow to net income ratio is 0.51, indicating moderate free cash flow relative to net earnings.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue713.04M691.30M688.57M673.70M567.44M
Gross Profit330.83M421.74M434.00M438.78M369.64M
EBITDA133.90M156.07M166.39M174.02M172.36M
Net Income83.76M96.89M116.10M120.35M111.46M
Balance Sheet
Total Assets1.14B1.05B1.04B992.77M856.88M
Cash, Cash Equivalents and Short-Term Investments273.65M217.84M206.39M253.16M215.01M
Total Debt15.64M18.54M13.33M16.26M20.01M
Total Liabilities209.36M148.56M146.88M177.60M153.55M
Stockholders Equity926.44M903.40M897.24M815.75M703.91M
Cash Flow
Free Cash Flow101.62M49.30M6.27M82.58M111.81M
Operating Cash Flow147.90M124.08M90.87M122.24M135.53M
Investing Cash Flow-128.64M-31.50M-94.68M-6.65M-134.43M
Financing Cash Flow-55.81M-52.70M-61.40M-55.89M-17.84M

Renishaw Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3670.00
Price Trends
50DMA
3300.30
Positive
100DMA
3053.70
Positive
200DMA
2959.12
Positive
Market Momentum
MACD
120.55
Positive
RSI
65.59
Neutral
STOCH
65.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RSW, the sentiment is Positive. The current price of 3670 is above the 20-day moving average (MA) of 3585.75, above the 50-day MA of 3300.30, and above the 200-day MA of 2959.12, indicating a bullish trend. The MACD of 120.55 indicates Positive momentum. The RSI at 65.59 is Neutral, neither overbought nor oversold. The STOCH value of 65.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:RSW.

Renishaw Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
£2.68B31.969.15%1.52%3.15%-13.57%
68
Neutral
£551.04M22.488.07%2.17%-3.23%58.34%
63
Neutral
£4.06B69.934.26%2.06%0.07%-78.33%
63
Neutral
£401.63M36.4812.24%1.78%5.46%-26.44%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
61
Neutral
£158.89M29.184.79%2.24%1.74%359.50%
55
Neutral
£100.90M197.220.81%1.41%-23.42%-94.25%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:RSW
Renishaw
3,670.00
351.65
10.60%
GB:GHH
Gooch & Housego
588.00
191.68
48.36%
GB:JDG
Judges Scientific
6,000.00
-3,164.39
-34.53%
GB:SOLI
Solid State
175.00
-78.38
-30.93%
GB:SXS
Spectris
4,098.00
1,673.52
69.03%
GB:DSCV
discoverIE Group plc
587.00
-43.23
-6.86%

Renishaw Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Renishaw Unveils Strategic Plans at Capital Markets Day
Positive
Jun 17, 2025

Renishaw hosted a Capital Markets Day to outline strategic progress and financial goals, including new product releases and changes to segmental reporting. The company aims to drive revenue growth through innovation, improve margins, and enhance shareholder returns with a new cost reduction program targeting £20 million in savings. The event highlighted significant investments in manufacturing capacity and introduced new business segments to better align with market demands.

The most recent analyst rating on (GB:RSW) stock is a Buy with a £4180.00 price target. To see the full list of analyst forecasts on Renishaw stock, see the GB:RSW Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Renishaw Reports Steady Q3 Growth Amid Strategic Restructuring
Positive
May 8, 2025

Renishaw plc reported steady progress in its third quarter, with revenue reaching £180.7 million, marking a 5% increase year-on-year. The company experienced growth in machine tool probes and position encoders, while also announcing the closure of its loss-making drug delivery segment in the Neurological business to enhance profitability. Despite challenges such as tariffs and increased labor costs, Renishaw maintains a strong balance sheet and continues to focus on productivity and strategic investments to support future growth.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 03, 2025